$NVO

NVO

Novo Nordisk A/S Sponsored ADR

本窗口内的全部观点与内容

截至 09-26
09-21
Schwab Network发布 2026-09-21
《Iran & China at Forefront of Trading Week, Critical Metals Rally & NVO Slides》
$NVO看跌
NVO股价承压,因市场认为其战略计划不够大胆或推进不够快,不过40美元处存在技术支撑。

现在来谈谈Novo,也就是此前的Novo Nordisk。该公司股价今早承压。市场似乎对Novo公布的下一阶段战略计划感到不满。

Now let's talk about Novo, formerly known as Novo Nordisk. The company's shares are under pressure this morning. The market appears to be dissatisfied with the plan revealed by Novo regarding its strategy for the next phase.

显然,他们的减肥药曾需求旺盛,至少在初期阶段是如此。但如今,竞争已经进入这一领域,并抢走了他们的部分市场份额。

It is clear that they saw a large demand for their weight loss drug, at least in its early stages. But now, competition has entered this field and captured part of their market share.

更早的记录
09-11
Schwab Network发布 2026-09-11
《Friday's First Moves: RH & KR Earnings Mixed, NVO Downgrade》Morgan Stanley
$NVO看跌
Morgan Stanley 将 NVO 下调至减持评级,40 美元目标价意味着较当前水平存在下行空间,原因是增长担忧与专利悬崖风险。

好。最后但同样重要的是,我们来看Novo Nordisk。我看到了一次下调评级,以及一个低于当前股价的目标价。

All right. And last but not least, we look at Novo Nordisk. I saw a downgrade and a price target below where we are now.

已显示 2 / 本页 2 条
看这只股票的全部记录